Type I interferon alpha family (IFN-alpha) (IFN-alpha)

The Type I interferon alpha (IFN-alpha) family consists of 13 closely related cytokine subtypes that play a pivotal role in the innate immune response against viral infections (UniProt, P01562). These proteins are primarily produced by plasmacytoid dendritic cells and signal through the heterodimeric IFN-alpha/beta receptor (IFNAR), activating the JAK-STAT pathway to induce an antiviral state in neighboring cells (PubMed, PMID: 30518544). Beyond their antiviral properties, IFN-alpha subtypes exhibit potent antiproliferative and immunomodulatory effects, making them useful in treating malignancies such as hairy cell leukemia and melanoma (StatPearls, NBK541017). However, chronic overproduction of IFN-alpha is a central driver in the pathogenesis of systemic lupus erythematosus (SLE), where it promotes the loss of self-tolerance (PubMed, PMID: 21873601). Therapeutic interventions include recombinant IFN-alpha proteins for viral and oncology indications, as well as monoclonal antibodies like sifalimumab or receptor-targeting agents like anifrolumab to treat autoimmune conditions (DrugBank, DB00105; FDA, 2021).

Other names

Interferon alphaIFN-αLeukocyte interferonType I interferon alpha

Recombinant IFN-alpha drugs act as agonists by binding to the IFNAR1/IFNAR2 receptor complex, triggering the phosphorylation of JAK1 and TYK2, which leads to the formation of the ISGF3 transcription factor complex and subsequent expression of antiviral genes (PubMed, PMID: 30518544). Conversely, therapeutic antibodies target the IFN-alpha ligands or the IFNAR receptor to block this signaling cascade in autoimmune diseases (PubMed, PMID: 21873601).